In India, Glenmark Pharmaceuticals (Glenmark), a pharmaceutical company focused on innovation, has introduced the first triple fixed-dose combination of Teneligliptin, Pioglitazone, and Metformin.
One frequently used DPP4 inhibitor is teneligliptin (Dipeptidyl Peptidase 4 inhibitor). The sustained release (SR) formulation of this FDC, sold under the trade name Zita-PioMet, contains the active ingredients teneligliptin (20 mg), pioglitazone (15 mg), and metformin (500 mg/1000 mg). With this, patients with Type 2 diabetes can more easily manage their glycemic control and reach the desired HbA1c within 24 weeks with the convenience of a once-daily dose.